"rationale","description","id","instanceType","uuid:ID","label","name"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","StudyDesign_1","StudyDesign","01e2027c-b27e-41ff-82d3-75e81d4a9f23","","Study Design 1"
